[Insulin and insulin-like growth factor pathway, a new targeted therapy in oncology].
The molecular biology of cancer has made it possible to identify new targets for attacking tumourous cells. One of these recently proposed targets is the insulin and insulin-like growth factor signaling pathway. This review describes its biological function, laboratory data, population studies that warn of its role in cancer, and the key elements of this signaling pathway: the ligands (insulin, IGF1, IGF2), its receptors and the cascade of intracellular signals that trigger its activation. Also reviewed are the different strategies under investigation for blocking it, some of which are already in phase III advanced studies. The preliminary data indicate that the medicines designed for blocking this pathway might be a new therapeutic weapon for oncology patients in the near future.
Bosch-Barrera
J
J
Departamento de oncología, Clínica Universidad de Navarra, Avenida Pio XII 36, Pamplona, Spain. jbosch@unav.es
Hernández
A
A
Abella
L E
LE
D006801:Humans; D007328:Insulin / Q000502:physiology*; D007329:Insulin Antagonists / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D015398:Signal Transduction; D013002:Somatomedins / Q000037:antagonists & inhibitors / Q000502:physiology*
D007328:Insulin; D007329:Insulin Antagonists; D013002:Somatomedins